Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
Sponsor: Vertex Pharmaceuticals Incorporated
This PHASE2 trial investigates Diabetic Peripheral Neuropathy and is currently completed. Vertex Pharmaceuticals Incorporated leads this study, which shows 17 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Nov 2024 — Aug 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
▶ Show 12 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Apr 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Feb 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vertex Pharmaceuticals Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .